Clinical Trial Update: Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant [Phase 1]

View source ↗

Summary

Phase 1 results evaluating sorafenib as maintenance therapy in patients with acute myeloid leukemia after allogeneic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED